Impact of Disease Management on Utilization and Adherence With Drugs and Tests

The case of diabetes treatment in the Florida: A Healthy State (FAHS) program

OBJECTIVE — The purpose of this study was to evaluate the effect of telephonic care management within a diabetes disease management program on adherence with treatment with hypoglycemic agents, ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), statins, and recommended laboratory tests in a Medicaid population.

RESEARCH DESIGN AND METHODS — A total of 2,598 patients with diabetes enrolled for at least 2 years in Florida: A Healthy State (FAHS), a large Medicaid disease management program, who received individualized telephonic care management were selected if they were eligible for at least 12 months before and 12 months after beginning care management. Patients were matched one-to-one on all baseline characteristics to 2,598 control patients. The impact of care management on utilization and adherence rates for diabetes-related medications and tests was analyzed with the difference-in-difference estimator.

RESULTS — Changes in utilization were evaluated separately for those who were characterized as adherent to treatment at baseline ("users") and those who were not ("nonusers"). Both groups achieved significant improvement in adherence between baseline and follow-up. Nonusers increased their overall hypoglycemic use by 0.7 script (P < 0.001), by 0.8 test for A1C (P < 0.001), by 0.7 test for lipids (P < 0.001). Users increased hypoglycemic use by 1.5 scripts (P < 0.001) and insulin use by 0.9 script (P < 0.001).

CONCLUSIONS — The FAHS telephonic care management intervention effectively inducted Medicaid patients with diabetes to begin treatment and improved adherence to oral hypoglycemic agents and recommended tests. It also substantially improved adherence among baseline insulin users.

From Pfizer Health Solutions, New York, New York. Corresponding author: Patrick Thiebaud, ptrck_thbd@yahoo.com. Received 2 November 2007 and accepted 22 May 2008. Published ahead of print at http://care.diabetesjournals.org on 3 June 2008. DOI: 10.2337/dc07-2118. © 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Diabetes Care 31:1717–1722, 2008

Lifelong treatment adherence and lifestyle modification are recognized as the most critical components of diabetes management. A number of randomized clinical trials provide evidence that medication adherence and adherence to recommended tests and services can effectively reduce complications and improve patient outcomes (1,2). Other studies have shown that adherence to medications, tests, and services is associated with decreased hospitalizations, complications, and costs among individuals with type 2 diabetes (3). Yet many patients fail to comply with recommended treatment guidelines (4,5). A recent meta-analysis suggested that mean adherence to treatment recommendations for patients with diabetes is only between 58 and 75% (6). Patient-centered interventions, such as disease management programs, can be used to improve adherence. They have been implemented to educate the chronically ill and to facilitate the management of their diseases (7). Their primary purpose is to monitor adherence to evidence-based treatment recommendations and to support the self-management skills to achieve adherence (8). There is evidence that disease management can improve the short-term processes of care, including medication adherence (9) and regular A1C and lipid testing (10).

To our knowledge, there are few published studies that examined the association between disease management program participation and adherence to medications and preventive health protocols in a Medicaid population (10). Medicaid populations and specifically beneficiaries with chronic conditions often have unique health care needs. Most beneficiaries have multiple chronic physical and behavioral health conditions, often complicated by difficult socioeconomic stressors (11). Beneficiaries with chronic conditions use health care and health-related services more frequently. Their care is on average more costly than that for beneficiaries without chronic conditions (11). A decreased ability to obtain timely, appropriate care and maintain continuity (12,13) contribute to these trends.

In this analysis we used data from the Florida: A Healthy State (FAHS) disease management program to assess the impact of educating Medicaid beneficiaries about their chronic diseases and improving their self-management abilities. We evaluated whether a guideline-driven comprehensive disease management program can improve the use of diabetes-related recommended tests, services, and medications among Medicaid Primary Care Case Management (PCCM) beneficiaries with diabetes.
**RESEARCH DESIGN AND METHODS**

**FAHS**
In 2001, Florida’s Agency for Health Care Administration (AHCA) and Pfizer partnered to create a statewide disease management program to address multiple chronic diseases. The duration of this program was more than 5 years, between July 2001 and December 2006. A detailed explanation of the program’s design, intervention and methods, and operations has been published elsewhere (14). Initially designed as a 2-year pilot, FAHS provided education and support to PCCM Medicaid beneficiaries. This clinically and financially successful program was extended for 2 more years in 2003 and subsequently transitioned to a new phase in 2005, led by the state, with Pfizer providing technical and program support. Briefly, AHCA and Pfizer designed a telephonic disease management model that reinforced goals already established between the health professional and patient to prevent exacerbations of chronic illness, support lifestyle change, and reduce the financial burden that chronic illness places on Florida’s Medicaid program. Only PCCM program participants with diabetes, heart failure, hypertension, or asthma were eligible for FAHS. AHCA identified these individuals and assigned a risk score (based on proprietary algorithms developed by outside vendors) reflecting clinical severity and the likelihood of incurring high medical costs. Note that these algorithms were based on claims only and were therefore not affected by changes in guidelines related to cholesterol or blood pressure levels. Moderate- and high-risk beneficiaries were recruited for telephonic care management. All beneficiaries, including those at low risk, received low-literacy health education mailings and had access to a 24-h nurse call center.

The comprehensive telephonic care management model used in FAHS was delivered by nurse care managers responsible for tailoring treatment plans to each patient (14). Care managers used a Web-based decision support application offering guideline-recommended treatments and screenings. Adherence to medications and staying current on all recommended tests and services were emphasized. Care managers influenced adherence in at least four ways. They encouraged patients to follow through on the provider’s orders and helped patients problem solve adherence issues. Nurses contacted the provider’s office directly with information that might result in a new medication or test order. They sent laboratory kits directly to the patients to ensure that the results were available. Care managers also had an indirect influence on adherence to guidelines by educating and empowering patients to partner with their providers.

**Analysis population**
This analysis was limited to patients with diabetes enrolled in FAHS. Over the 5-year life of the program, 24,979 (13%) program participants had diabetes. Of these individuals, 7,517 (30%) were of moderate or high risk. As such, they were eligible to participate in the telephonic care management component of the program. Patients could opt out of care management voluntarily. The final sample consisted of 2,598 individuals who did not decline care management and were enrolled in FAHS for at least 12 months before participating in care management and at least 12 months after initiating care management.

These 2,598 beneficiaries were matched 1-to-1 to a control group of moderate- to high-risk beneficiaries with diabetes who were never care managed in the program. Beneficiaries in both the treatment and control groups were continuously eligible for FAHS for at least 2 years. Among the treatment group, the index date was the day care management began. A random observation window of 2 years was used for those in the control group. For them, the index date was simply the midpoint of this 2-year interval. These 2 years could be any continuous period between January 2002 and December 2006.

**Outcome measures**
In this research we considered several types of outcome measures: changes in utilization and adherence with drugs recommended for diabetes treatment as well as changes in patterns of annual laboratory tests. Hypoglycemic agents (both insulin and oral antidiabetic drugs), statins, ACE inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) were considered separately. Drug utilization and adher-

---

**Table 1—Sample characteristics at baseline: demographics, comorbidities, non–drug health care utilization**

|                                | Group 1: care managed | Group 2: not care managed | P value* |
|--------------------------------|-----------------------|---------------------------|----------|
| Demographics                   |                       |                           |          |
| Age (years)                    | 52.8                  | 51.1                      | <0.001   |
| Sex (% female)                 | 78.3                  | 70.0                      | <0.001   |
| Medicaid eligibility under     |                       |                           |          |
| TANF                           | 7.8                   | 14.6                      | <0.001   |
| SSI                            | 86.8                  | 80.0                      | <0.001   |
| Both TANF and SSI              | 5.4                   | 5.4                       | 0.951    |
| Race (%)                       |                       |                           |          |
| Black                          | 25.8                  | 24.2                      | 0.189    |
| Hispanic                       | 5.7                   | 5.7                       | 0.905    |
| White                          | 35.5                  | 38.1                      | 0.066    |
| Other                          | 32.9                  | 32.1                      | 0.534    |
| Comorbidities                  |                       |                           |          |
| Hypertension diagnosis (%)     | 16.7                  | 11.4                      | <0.001   |
| Dyslipidemia diagnosis (%)     | 5.7                   | 4.5                       | 0.059    |
| Sum Charlson index             | 0.6                   | 0.4                       | <0.001   |
| Myocardial infarction (%)      | 0.6                   | 0.3                       | 0.101    |
| Congestive heart failure (%)   | 2.8                   | 0.8                       | <0.001   |
| Peripheral vascular (%)        | 1.2                   | 0.6                       | 0.020    |
| Non–drug health care utilization |                      |                           |          |
| No. emergency room visits      | 1.4                   | 1.3                       | 0.474    |
| No. inpatient stays            | 0.4                   | 0.4                       | 0.543    |
| No. outpatient visits          | 10.8                  | 9.3                       | <0.001   |
| No. other services             | 32.6                  | 30.7                      | 0.086    |

*χ² test or Student’s t test. SSI, Supplemental Security Income; TANF, Temporary Aid to Needy Families.
ence measures were constructed for five classes of hypoglycemic agents (biguanides, sulfonylureas, thiazolidinediones, meglitinides, and insulin) and also for statins, ACEIs, and ARBs. Drug utilization was measured as the sum of days supplied with a refill in a particular drug class over a period of 1 year pre- and post-index. Adherence was measured with the medication possession ratio (MPR) (15). The MPR was calculated as the sum of days supplied, by class, over a 1-year period divided by 365. The computation of an MPR for overall hypoglycemic treatment, including the combination of hypoglycemic agents, was more complex. We assumed that a prescription for a different class of agents represented a switch to a new class if the new prescription was filled 90 days after that for the previous drug. If the interval was shorter, the patient was assumed to be taking two drugs simultaneously, and MPRs were averaged. MPRs were simply added to each other.

Recommended laboratory tests and screening procedures (16,17) were also evaluated. Laboratory codes were used to identify A1C, lipid profile, and microalbumin tests, and retinal examinations were identified with CPT codes. Their utilization was measured as a count of the number of claims over 1 year.

**Statistical analysis**

To determine the impact of care management, patients who were care managed were compared with patients who were not in a case-control study. To ensure that both groups were similar, patients were matched pairwise with a minimum distance estimator (18). Matching was based on baseline characteristics including health care utilization (i.e., health services, laboratory, and pharmacy), comorbidity burden, age, sex, race, and Medicaid enrollment status (Supplemental Security Income or Temporary Assistance for Needy Families). Diagnoses were used as a proxy for severity of disease and were combined to create a Charlson comorbidity index (19). Patients in both groups had identical health care benefits and were treated over the same period of time, thus eliminating the impact of changes in the health care system, health care benefits, or treatment guidelines. Our analysis proceeded in two steps. First, we compared key baseline characteristics and health care utilization and baseline use of glycemic control, antihypertensive, and cholesterol-lowering medications. Then, we tested the impact of care management on the number of claims over a 1-year period.

| Hypoglycemic agent | Care managed | Not care managed | P value* | Mean MPR | Proportion of users with MPR > 80% |
|-------------------|-------------|------------------|---------|---------|-------------------------------|
| All hypoglycemic agents | 86.6 | 77.5 | 0.001 | 0.01 | 0.85 |
| Biguanide (metformin) | 41.6 | 34.9 | 0.001 | 0.01 | 0.85 |
| Meglitinide | 3.0 | 2.9 | 0.742 | 0.01 | 0.85 |
| Sulfonylurea | 48.0 | 42.5 | 0.001 | 0.01 | 0.85 |
| Thiazolidinedione | 30.5 | 29.4 | 0.348 | 0.01 | 0.85 |
| Insulin | 30.6 | 28.5 | 0.088 | 0.01 | 0.85 |
| Cardiovascular medication | | | | | |
| ACEI | 48.6 | 33.1 | 0.001 | 0.01 | 0.85 |
| ARB | 14.8 | 10.9 | 0.001 | 0.01 | 0.85 |
| Statin | 46.7 | 33.5 | 0.001 | 0.01 | 0.85 |
| Laboratory test | | | | | |
| A1C | 67.5 | 61.8 | 0.001 | 0.01 | 0.85 |
| Lipid profile | 66.2 | 61.4 | 0.001 | 0.01 | 0.85 |
| Microalbumin tests | 15.4 | 15.3 | 0.847 | 0.01 | 0.85 |
| Retinal examinations | 45.8 | 37.1 | 0.001 | 0.01 | 0.85 |

The number of patients in each category can be derived from the total sample size multiplied by the proportion of users. Users are patients who filled one or more prescriptions in the drug class considered in each category of users. The number of patients in each category can be derived from the total sample size multiplied by the proportion of users. Users are patients who filled one or more prescriptions in the drug class considered in each category of users.
Effect of care management on adherence

Table 3—Hypoglycemic and cardiovascular drugs: changes in utilization and adherence

|                              | Nonusers at baseline | Users at baseline only |
|------------------------------|----------------------|------------------------|
|                              | Care managed vs. not care managed | Care managed vs. not care managed | P value | P value |
| Number of fills*             |                      |                        |          |        |
| Hypoglycemic drug prescriptions |                      |                        |          |        |
| All hypoglycemic agents      | 0.7                  | 0.041                  | 1.5      | <0.001 |
| Biguanide (metformin)        | 0.5                  | 0.001                  | 0.1      | 0.548  |
| Meglitinide                  | 0.03                 | 0.001                  | 0.2      | 0.754  |
| Sulfonylurea                 | 0.6                  | 0.001                  | 0.3      | 0.02   |
| Thiazolidinedione            | 0.2                  | 0.005                  | 0.3      | 0.109  |
| Insulin                      | 0.1                  | 0.214                  | 0.9      | <0.001 |
| Cardiovascular medication prescriptions |          |                        |          |        |
| ACEI                         | 0.7                  | <0.001                 | 0.3      | 0.02   |
| ARB                          | 0.2                  | <0.001                 | 0.4      | 0.107  |
| Statin                       | 0.7                  | <0.001                 | 0.06     | 0.676  |
| Days supply*                 |                      |                        |          |        |
| Hypoglycemic drug prescriptions |                      |                        |          |        |
| All hypoglycemic agents      | 17.3                 | 0.064                  | 47.0     | <0.001 |
| Biguanide (metformin)        | 14.6                 | <0.001                 | 3.4      | 0.439  |
| Meglitinide                  | 1.1                  | 0.037                  | 5.9      | 0.727  |
| Sulfonylurea                 | 17.9                 | <0.001                 | 11.1     | 0.009  |
| Thiazolidinedione            | 6.7                  | 0.005                  | 8.9      | 0.104  |
| Insulin                      | 0.2                  | 0.918                  | 34.0     | <0.001 |
| Cardiovascular medication prescriptions |          |                        |          |        |
| ACEI                         | 22.3                 | <0.001                 | 9.9      | 0.018  |
| ARB                          | 5.7                  | <0.001                 | 11.0     | 0.102  |
| Statin                       | 19.2                 | <0.001                 | 1.8      | 0.646  |
| MPR (% days covered)         |                      |                        |          |        |
| Hypoglycemic drug prescriptions |                      |                        |          |        |
| All hypoglycemic agents      | 8.7                  | <0.001                 | 6.9      | <0.001 |
| Biguanide (metformin)        | 4.5                  | <0.001                 | -0.4     | 0.740  |
| Meglitinide                  | 0.3                  | 0.014                  | 0.2      | 0.968  |
| Sulfonylurea                 | 5.7                  | <0.001                 | 1.3      | 0.231  |
| Thiazolidinedione            | 2.4                  | <0.001                 | 1.0      | 0.488  |
| Insulin                      | 1.3                  | 0.004                  | 5.7      | <0.001 |
| Cardiovascular medication prescriptions |          |                        |          |        |
| ACEI                         | 6.2                  | <0.001                 | 4.3      | 0.685  |
| ARB                          | 1.3                  | 0.001                  | 0.7      | 0.7003 |
| Statin                       | 5.4                  | <0.001                 | -2.0     | 0.064  |

The difference-in-differences estimator was used here. Results are expressed as the change in utilization or MPR in the care-managed group relative to the not–care managed group. *Over a 12-month period.

and antidysslipidemia agents and recommended annual diabetes-related tests. The second step evaluated changes over time in two categories of patients: those who reported using diabetes-related medications or tests at baseline (users) and those who reported not using such drugs or tests at baseline (nonusers). Users were defined for each drug class (e.g., insulin, thiazolidinediones, and statins) as patients who filled at least one prescription at baseline. Nonusers were patients who did not fill any prescription in the drug class considered. For tests, users were defined as patients who received a least one test at baseline. Changes in utilization and adherence were calculated as the difference between year 2 (follow-up) and year 1 (baseline) values. We compared the changes in those care managed versus those not care managed with the difference-in-differences estimator (20).

RESULTS—At baseline, care-managed patients, although similar to never care-managed patients (Table 1), were slightly older (52.8 vs. 51.1 years; P < 0.001), more likely to be female (78.3 vs. 70.0%; P < 0.001), and more likely to be eligible for Medicaid as Supplemental Security Income beneficiaries (86.8 vs. 80.0%; P < 0.001). More care-managed patients received a diagnosis of hypertension, congestive heart failure, or peripheral artery disease and had slightly higher comorbidity scores. These differences as well as differences in race and most nondrug utilization were small, although sometimes statistically significant, and were controlled for in our model.

Table 2 shows baseline values for drug and laboratory test utilization (proportion of users and average utilization among users) and adherence with drug treatment (as average MPR among users and proportion of users with MPR ≥80%). Care-managed patients were more likely to have used a hypoglycemic agent, an ACEI, an ARB, or a statin at baseline, although average utilization and adherence were not significantly different between groups. The same pattern occurred with annual laboratory test utilization.

In the explanatory analysis, we quantified improvements in utilization and adherence with drug treatments separately for baseline nonusers and users (Table 3). It is important to realize that in this table the impact of care management is measured by the change in utilization for patients receiving treatment relative to control subjects—not relative to baseline (group-specific values are available from the authors). Care-managed patients reporting no utilization at baseline (nonusers) were more likely to fill prescriptions, to maintain more days of supply, and to have higher MPR than patients who were not care managed. Care-managed patients filled an average of 0.7 script for hypoglycemic agents (P = 0.041), 0.7 script for ACEIs (P < 0.001), and 0.7 script for statins (P < 0.001) more than non–care-managed patients. The increase in days of supply and adherence paralleled the rise in number of prescriptions filled.

Care-managed patients reporting some baseline utilization (users) achieved a significant increase in the number of fills and days’ supply of insulin, sulfonylurea, and ACEI. There was also a significant increase in MPR, with the increase concentrated in the insulin class. Compared with baseline nonusers, who increased by only a small amount of refill and days’ supply (0.1 fill and 0.2 days’ supply) and achieved a modest (1.3%) increase in
MPR, baseline users added significantly to their regimen (0.9 script and 34.0 days’ supply), resulting in a 3.7% increase in MPR.

Next, we determined the impact of care management on recommended laboratory tests and retinal examinations (Table 4). This analysis was also divided according to baseline utilization. Comparisons are presented for nonusers at baseline and for baseline users with one test, two tests, or three or more tests within the 12 months before the initiation of the program. Care-managed patients with no tests at baseline experienced a significant increase in the number of A1C, lipid, and microalbuminuria tests and retinal examinations performed (0.75 for A1C, 0.67 for lipid, 0.14 for microalbumin, and 0.54 for retinal examination; all with P < 0.001). The pattern was more complex among baseline users. The general pattern that emerged was that care-managed baseline users with one test at baseline experienced increases in A1C and lipid testing compared with baseline users who were not care managed. Conversely, care-managed baseline users with more than two tests experienced significant decreases in test utilization compared with baseline users who were not care managed.

**CONCLUSIONS**—Many chronically ill individuals fail to adhere to recommended medication and testing regimens. This article demonstrates that, among patients with diabetes, telephonic disease management improved adherence to both. Although there have been studies of type 2 diabetes that have addressed adherence to hypoglycemic medications (21) and studies that have looked at adherence to recommended tests and screenings (22,23), this study is unique in that it looked at both to create a broader view of treatment adherence. Another distinguishing feature of this study is that it is the first to our knowledge that evaluated the association between participation in telephonic disease management and treatment adherence among Medicaid beneficiaries with diabetes.

Our findings indicate that care-managed patients increased their drug utilization compared with matched control subjects. First, patients who filled no prescriptions for a hypoglycemic agent, an ACEI, an ARB, or a statin in the year before, the number of prescriptions filled during the study period remained low on average. The notable exception to this pattern was insulin treatment. Insulin utilization and adherence increased significantly among baseline users. This result is particularly important, as it probably applies to patients who typically have more severe diabetes.

Care management also affected receipt of laboratory tests and screenings. Patients who had no test at baseline were more likely to have at least one test performed during the follow-up period. In contrast, compared with non–care-managed patients, care-managed patients who had two or more tests at baseline had fewer tests performed during follow-up. This may indicate that baseline test users received unnecessary tests at baseline and that care management reduced the use of unnecessary services.

The analysis also has limitations. First, assignment to treatment and control groups was not random, and beneficiaries were allowed to opt out of the program. Although differences in baseline values between members of the treatment and control groups were small, these differences could, in principle, bias our estimates. However, as we relied on a difference-in-differences estimator, it is the change in the values of predictors and outcomes that matters. The key issue is whether there is any evidence that disease and utilization trajectories over time among the treatment group would have been different from those of control subjects in the absence of treatment. Careful review of baseline values indicated that observed differences between groups were not large enough to suggest different disease progression trajectories and are therefore unlikely to have introduced significant bias. Second, there is a certain degree of imprecision regarding diagnoses in claims data, as physicians rarely record the full five digits of diabetes diagnoses, and we could not perform a separate analysis on type 1 and type 2 diabetic patients to determine whether the observed increase in adherence to insulin among baseline users might be attributable to one of these groups.

A key question given the exclusion criteria used to create our sample is whether our results can be generalized to all diabetic patients in this Medicaid pop-

### Table 4—Laboratory tests: changes in utilization

| Table 4—Laboratory tests: changes in utilization |
|-----------------------------------------------|
| Patients with 0 tests at baseline              |
| A1C                                           |
| Lipid panel                                   |
| Microalbumin test                             |
| Retinal examinations                          |
| Care managed vs. not care managed‡            |
| Patients with 1 test at baseline              |
| A1C                                           |
| Lipid panel                                   |
| Microalbumin test                             |
| Retinal examinations                          |
| Patients with 2 tests at baseline             |
| A1C                                           |
| Lipid panel                                   |
| Microalbumin test                             |
| Retinal examinations                          |
| Patients with ≥3 tests at baseline            |
| A1C                                           |
| Lipid panel                                   |
| Microalbumin test                             |
| Retinal examinations                          |

The difference-in-differences estimator was used here. Results are expressed as the change in utilization or MPR in the care-managed group relative to the not–care-managed group. *Number of care-managed patients. †Number of tests received over 12 months.
Effect of care management on adherence

Epstein RS: Impact of medication adherence on hospitalization risk and health-care cost. *Med Care* 43:521–530, 2005

5. Massing MW, Schenck AP, Henley NS, Simpson RJ, Carter-Edwards L: Lipid testing among patients with diabetes who received diabetes care from primary care physicians. *Diabetes Care* 26:1369–1373, 2003

6. DiMatteo MR: Variations in patient’s adherence to medical recommendations: a quantitative review of 30 years of research. *Med Care* 42:200–209, 2004

7. Fitzner K, Fox K, Schmidt J, Roberts M, Rindse D, Hay J: Implementation and outcomes of commercial disease management programs in the United States: the disease management outcomes consolidation survey. *Dis Manage* 8:253–264, 2005

8. Fetterlof DE, Jennings S. Outcomes Guidelines Report, 1st ed. Washington, DC, Disease Management Association of America, 2006

9. Congressional Budget Office: An analysis of the literature on disease management programs [article online], 2004. Available from http://www.cbo.gov/ftpdocs/59xx/doc5909/10-13-diseasemgmnt.pdf. Accessed 13 October 2004

10. Coberley C, Hamar B, Gandy B, Orr P, Coberley S, McGinnis M, Hudson L, Forman S, Shurney D, Pope J: Impact of telephonic interventions on glycosylated hemoglobin and low-density lipoprotein cholesterol testing. *Am J Manag Care* 13:188–192, 2007

11. Williams D: Medicaid disease management: issues and promises. Kaiser Commission on Medicaid and the Uninsured [article online], 2004. Available at http://www.kff.org/medicaid/upload/Medicaid-Disease-Management-Issues-and-Promises-Issue-Paper.pdf. Accessed 5 April 2007

12. Zuckerman S, McFeeters J, Cunningham P, Nichols L: Changes in Medicaid physician fees 1998–2003: implications for physician participation [article online]. 2004. Health Affairs Web exclusive. Available from http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w4.374. Accessed 23 June 2004

13. Schoen C, DesRoches C: Uninsured and unstably insured: the importance of continuous insurance coverage. *Health Serv Res* 35:187–206, 2000

14. Afifi AA, Morsosky DE, Kominski GF, Kotlerman JB: Impact of disease management on health care utilization: evidence from “Florida: A Healthy State (FAHS)” Medicaid program. *Prev Med* 44:547–553, 2007

15. Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. *J Clin Epidemiol* 50:105–16, 1997

16. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 25:S4–S51, 2002

17. American Diabetes Association: Standards of medical care in diabetes—2007. *Diabetes Care* 30:S4–S51, 2007

18. Bergstrahl EJ, Kosanke JL: Computerized matching of controls. Section of Biostatistics Technical Report 56. Rochester, MN, Mayo Foundation, 1995

19. Charlson ME, Pompei P, Ales KL, McKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chron Dis* 40:373–383, 1987

20. Donald SG, Lang K: Insurers and patients: factors associated with health care utilization: evidence from continuous insurance coverage. *Med Care* 118:27S–34S, 2005

21. Espinet LM, Osmick W, Culler SD, Cook CB, El-Kebbi IM, Gallina DL, Barnes C, Phillips LS: Patient adherence improves glycemic control. *Diabetes Educ* 31:240–250, 2005

22. Sloen FA, Bethel A, Lee PP, Brown DS, Feinglos MN: Adherence to guidelines and its effect on hospitalizations and complications of type 2 diabetes. *Rev Diabet Stud* 1:29–38, 2004

References

1. The Diabetes Control and Complication Trial Research Group (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993

2. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 348:383–393, 2003

3. Pladevall M, Divine G, Williams LK, Xi H, Potts LA, Laffata JE: Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. *Diabetes Care* 27:2800–2805, 2004

4. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS: Impact of medication adherence on hospitalization risk and health-care cost. *Med Care* 43:521–530, 2005

5. Massing MW, Schenck AP, Henley NS, Simpson RJ, Carter-Edwards L: Lipid testing among patients with diabetes who received diabetes care from primary care physicians. *Diabetes Care* 26:1369–1373, 2003

6. DiMatteo MR: Variations in patient’s adherence to medical recommendations: a quantitative review of 30 years of research. *Med Care* 42:200–209, 2004

7. Fitzner K, Fox K, Schmidt J, Roberts M, Rindse D, Hay J: Implementation and outcomes of commercial disease management programs in the United States: the disease management outcomes consolidation survey. *Dis Manage* 8:253–264, 2005

8. Fetterlof DE, Jennings S. Outcomes Guidelines Report, 1st ed. Washington, DC, Disease Management Association of America, 2006

9. Congressional Budget Office: An analysis of the literature on disease management programs [article online], 2004. Available from http://www.cbo.gov/ftpdocs/59xx/doc5909/10-13-diseasemgmnt.pdf. Accessed 13 October 2004

10. Coberley C, Hamar B, Gandy B, Orr P, Coberley S, McGinnis M, Hudson L, Forman S, Shurney D, Pope J: Impact of telephonic interventions on glycosylated hemoglobin and low-density lipoprotein cholesterol testing. *Am J Manag Care* 13:188–192, 2007

11. Williams D: Medicaid disease management: issues and promises. Kaiser Commission on Medicaid and the Uninsured [article online], 2004. Available at http://www.kff.org/medicaid/upload/Medicaid-Disease-Management-Issues-and-Promises-Issue-Paper.pdf. Accessed 5 April 2007

12. Zuckerman S, McFeeters J, Cunningham P, Nichols L: Changes in Medicaid physician fees 1998–2003: implications for physician participation [article online]. 2004. Health Affairs Web exclusive. Available from http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w4.374. Accessed 23 June 2004

13. Schoen C, DesRoches C: Uninsured and unstably insured: the importance of continuous insurance coverage. *Health Serv Res* 35:187–206, 2000

14. Afifi AA, Morsosky DE, Kominski GF, Kotlerman JB: Impact of disease management on health care utilization: evidence from “Florida: A Healthy State (FAHS)” Medicaid program. *Prev Med* 44:547–553, 2007

15. Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. *J Clin Epidemiol* 50:105–16, 1997

16. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 25:S4–S51, 2002

17. American Diabetes Association: Standards of medical care in diabetes—2007. *Diabetes Care* 30:S4–S51, 2007

18. Bergstrahl EJ, Kosanke JL: Computerized matching of controls. Section of Biostatistics Technical Report 56. Rochester, MN, Mayo Foundation, 1995

19. Charlson ME, Pompei P, Ales KL, McKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chron Dis* 40:373–383, 1987

20. Donald SG, Lang K: Insurers and patients: factors associated with health care utilization: evidence from continuous insurance coverage. *Med Care* 118:27S–34S, 2005

21. Rubin RR: Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. *Am J Med* 118:27S–34S, 2005

22. Espinet LM, Osmick W, Culler SD, Cook CB, El-Kebbi IM, Gallina DL, Barnes C, Phillips LS: Patient adherence improves glycemic control. *Diabetes Educ* 31:240–250, 2005

23. Patric K, Stickles JD, Turpin RS, Simmons JB, Jackson J, Bridges E, Shah M: Diabetes disease management in Medicaid managed care: a program evaluation. *Dis Manage* 9:144–156, 2006

24. Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi IM, Gallina DL, Barnes C, Phillips LS: Patient adherence improves glycemic control. *Diabetes Educ* 31:240–250, 2005

25. Sloen FA, Bethel A, Lee PP, Brown DS, Feinglos MN: Adherence to guidelines and its effect on hospitalizations and complications of type 2 diabetes. *Rev Diab Educ* 1:29–38, 2004